Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.40
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.50
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0798
    +0.0005 (+0.04%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2640
    +0.0018 (+0.14%)
     
  • USD/JPY

    151.2380
    -0.1340 (-0.09%)
     
  • Bitcoin USD

    70,533.20
    -406.05 (-0.57%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

We expect BioNTech SE BNTX to surpass expectations when it reports first-quarter 2021 results.

The company’s surprise record has been mixed so far as its bottom line beat the Zacks Consensus Estimate in two of the trailing four quarters and lagged the same on the other two occasions, the average beat being 68.17%. In the last-reported quarter, BioNTech delivered an earnings surprise of 428.07%.

Shares of BioNTech have skyrocketed 131% so far this year against the industry’s decrease of 2%.

price chart for BNTX
price chart for BNTX


Let’s see how things are shaping up for the quarter to be reported.

Factors at Play

BioNTech and partner Pfizer’s PFE two-shot COVID-19 vaccine, BNT162b2, is now approved for emergency/temporary use in several countries. Vaccine rollouts are in full swing as millions of doses have already been supplied to various countries across the globe. A key contributor to BioNTech’s sales in the first quarter of 2021 should be BNT162b2.

BioNTech, along with its collaboration partners, has supplied more than 200 million doses of BNT162b2 worldwide, as of March 23, 2021. The company and Pfizer have signed orders to provide 1.4 billion doses of BNT162b2 for delivery in 2021.

In April 2021, BioNTech/Pfizer agreed to supply an additional 100 million doses of their COVID-19 vaccine, Comirnaty, to the 27 European Union member states, bringing the total tally to 600 million doses, all of which are expected to be delivered by the end of 2021.

Meanwhile, BioNTech/Pfizer have requested amendments to the Emergency Use Authorization for BNT162b2 to expand its use in adolescents of 12 to 15 years of age. Investors will be keen to get an update on the same at the upcoming earnings call.

Also, BioNTech has a collaboration with Fosun Pharma for BNT162b2 in China. Collaboration revenues are expected to have increased in the to-be-reported quarter from the prior-year period’s reported number following the above-mentioned partnerships.

This apart, BioNTech’s pipeline boasts of several candidates, such as BNT111, the company’s mRNA-based FixVac cancer vaccine program, and BNT113, BNT122 and BNT311, to name a few which are in early- to mid-stage studies for addressing various oncological indications. An update on the above-mentioned programs is expected during the upcoming earnings call.

The study and developmental activities related to the company’s pipeline candidates are likely to have escalated its operating expenses in the to-be-reported quarter.

Why a Likely Positive Surprise?

Our proven model predicts an earnings beat for BioNTech this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Earnings ESP: BioNTech has an Earnings ESP of +22.76% as the Zacks Consensus Estimate stands at $3.44 per share while the Most Accurate Estimate is pegged at $4.22 per share.

Zacks Rank: BioNTech has a Zacks Rank #3.

BioNTech SE Sponsored ADR Price and Consensus

BioNTech SE Sponsored ADR Price and Consensus
BioNTech SE Sponsored ADR Price and Consensus


BioNTech SE Sponsored ADR price-consensus-chart | BioNTech SE Sponsored ADR Quote

Other Stocks to Consider

Here are some other drug/biotech stocks that have the right combination of elements to beat on earnings this time around:

Axsome Therapeutics, Inc. AXSM with an Earnings ESP of +23.83% and a Zacks Rank #3. The company is scheduled to report earnings on May 10.

Milestone Pharmaceuticals Inc. MIST has an Earnings ESP of +19.21% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report

BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report

Milestone Pharmaceuticals Inc. (MIST) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement